checkAd

    EQS-News  117  0 Kommentare Biotest AG: Annual General Meeting approves dividend distribution

    Für Sie zusammengefasst
    • Annual General Meeting approves dividend distribution
    • Dividend of €0.04 per preference share for 2023 and 2022
    • Shareholders approve actions of Executive Board and Supervisory Board

    EQS-News: Biotest AG / Key word(s): AGM/EGM
    Biotest AG: Annual General Meeting approves dividend distribution

    07.05.2024 / 20:26 CET/CEST
    The issuer is solely responsible for the content of this announcement.


     

    PRESS RELEASE

    Biotest AG: Annual General Meeting approves dividend distribution

    • Distribution of EUR 0.04 per preference share for each of the years 2023 and 2022
    • Broad majority in the vote in line with the management's proposals

    Dreieich, 07 May 2024. At the Annual General Meeting on May 7, 2024, the shareholders of Biotest AG resolved to distribute a dividend of € 0.04 per preference share for the years 2023 and 2022. A total of 76.19% of the share capital was represented. The resolution on the appropriation of net profit was passed with 99.93% approval.

    The shareholders approved the actions of the members of the Executive Board and Supervisory Board for the 2023 financial year by a large majority. All resolutions on the other items on the agenda submitted for resolution were also passed by a large majority in accordance with the management's proposals.

    The Annual General Meeting speech by Mr. Peter Janssen, CEO of Biotest AG, is available at Annual General Meeting 2024 Shareholders' Meeting 2024 (biotest.com).

     

    About Biotest

    Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Biotest AG: Annual General Meeting approves dividend distribution EQS-News: Biotest AG / Key word(s): AGM/EGM Biotest AG: Annual General Meeting approves dividend distribution 07.05.2024 / 20:26 CET/CEST The issuer is solely responsible for the content of this announcement.   PRESS RELEASE Biotest AG: Annual …